Junior Product Manager

City Therapeutics raises $200M for RNAi beyond the liver. City Therapeutics' $200 million IPO backs RNAi development beyond the liver, with an anticoagulant contender and partnerships in eye and brain diseases. Key facts. * IPO proceeds: City Therapeutics raised $200 million in an upsized initial public offering. * Lead therapy: An RNA interference candidate could become an alternative to blockbuster-selling anticoagulants. * Eye-disease partnership: City Therapeutics has a partnership with Bausch + Lomb in eye diseases. * Central nervous system partnership: City Therapeutics has a partnership with Biogen in central nervous system disorders. City Therapeutics raised $200 million in an upsized initial public offering to advance RNA interference medicines, including a platform aimed at reaching tissues beyond the liver. City Therapeutics has raised $200 million in an upsized initial public offering, securing capital for a drug-development strategy that reaches beyond the liver, an important destination for RNA interference medicines. Its investment case combines a lead therapy that could offer an alternative to established anticoagulants with technology intended to deliver gene-silencing drugs to other tissues. The financing addresses a central challenge in biotechnology: turning a promising way of intervening in disease into medicines that can reach the right cells safely and reliably. City also has partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. Those relationships give the platform a broader development footprint, but they do not establish that its experimental treatments will work. More capital, but no shortcut to clinical evidence. The upsized offering raised $200 million, according to MedCity News. The financing gives City resources to pursue its pipeline and delivery technology. It does not, on its own, resolve the scientific and clinical risks that will determine their value. The distinction matters because an IPO measures a company's ability to secure funding, not the effectiveness of its medicines. A larger offering can support development work, but investors still need evidence that a treatment produces its intended biological effect and that the effect translates into a benefit for patients. The supplied offering details do not establish a share price, valuation, net proceeds after expenses or a program-by-program spending plan. Without those terms, the amount raised cannot support a precise judgment about dilution, cash runway or how much capital will reach any particular therapy. The sounder focus is what evidence the financing may help City generate. Why delivery beyond the liver matters. RNA interference, or RNAi, is a way to reduce production of a selected protein by targeting the molecular instructions used to make it. Rather than directly blocking a protein after it has been produced, an RNAi medicine seeks to interrupt the process upstream. Its therapeutic usefulness depends on choosing a suitable target and delivering the treatment to the cells that matter. Delivery is therefore part of the medicine's core design, not merely a packaging problem. A treatment must reach the relevant tissue, enter the appropriate cells and remain active long enough to produce a useful effect. Success at silencing a target in one setting does not automatically establish that the same approach will succeed elsewhere in the body. For City, expansion beyond the liver could widen the range of diseases its technology can address. But that opportunity also sets a demanding standard of proof. Investors will need to distinguish evidence that a drug reaches a tissue from evidence that it changes the course of disease. Both are important, and neither should be assumed from the platform's ambition. The anticoagulant opportunity rests on patient benefit. City's lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. That places the program against an established treatment category rather than a market with no existing options. The commercial opportunity is meaningful in principle, but the description of a potential alternative is not evidence of superiority. City's lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. Anticoagulants reduce the blood's ability to form clots. Their clinical use involves balancing protection against harmful clotting with the risk of bleeding. Any new approach seeking a role in that treatment landscape must demonstrate a useful balance of benefit and risk in the patients for whom it is intended. For an RNAi candidate, the connection between gene silencing and patient outcomes will be central. Showing that a target has been suppressed is different from showing that patients experience fewer harmful events or an acceptable safety profile. Duration of action and the ability to manage treatment around changing medical needs would also be relevant questions, rather than advantages investors should presume. The available facts do not identify the lead therapy's target, trial stage, dosing schedule or clinical results. They therefore support an opportunity to investigate, not a forecast that City will displace existing medicines. Partnerships broaden the platform's reach. The Bausch + Lomb and Biogen partnerships extend City's work into eye diseases and central nervous system disorders, respectively. They provide concrete examples of how the company's RNAi design and delivery technology is being pursued outside its lead program. These relationships matter because a platform business depends on more than the prospects of an individual drug. If technology can support useful medicines across distinct tissues and diseases, it may create additional development opportunities. Conversely, a result in one program may say little about another when the target cells, delivery requirements and disease biology differ. The partnerships should not be treated as interchangeable proof points. Work in eye disease cannot by itself validate a treatment for a central nervous system disorder, and neither establishes the clinical prospects of the anticoagulant alternative. No partnership payments, milestone amounts or royalty terms are supplied. Investors consequently cannot use these relationships to calculate a dependable stream of future cash. Their demonstrated significance here is the breadth of the development relationships, not a quantifiable contribution to revenue. What investors should watch after the IPO. The next useful disclosures would connect City's financing to a clear development plan: which programs it intends to prioritize, what studies are designed to establish and how spending is divided between individual candidates and the delivery platform. Those details would help investors judge whether the company is pursuing a focused set of testable objectives. For the lead therapy, attention should fall on clinical evidence relevant to anticoagulant use, rather than molecular activity alone. For the broader platform, the important question is whether delivery outside the liver can produce reproducible, therapeutically useful results without unacceptable safety costs. City's $200 million IPO provides capital to pursue those questions. Its partnerships broaden the scope of the effort, while the lead program gives investors a specific potential commercial application to assess. The financing is a consequential step, but the investment case ultimately depends on what the company can demonstrate with that capital - not simply how much it raised. Frequently asked questions. How much did City Therapeutics raise in its IPO? City Therapeutics raised $200 million in an upsized initial public offering. The financing supports a company developing RNA interference medicines and technology intended to reach tissues beyond the liver. The available facts do not specify the offering's share price, valuation, net proceeds after expenses or allocation of funding among programs. What is RNA interference? RNA interference, or RNAi, reduces production of a selected protein by targeting the molecular instructions used to make it. For a treatment to work, it must reach the appropriate cells and produce a useful biological effect. Successful target suppression must then translate into meaningful patient benefit with an acceptable safety profile. Why is City Therapeutics pursuing RNAi beyond the liver? Reaching tissues beyond the liver could allow City Therapeutics to pursue a broader range of diseases. Delivery is a central challenge because an RNAi medicine must enter the relevant cells to act. Evidence of delivery is important, but it does not by itself establish that a treatment improves patient outcomes. What is the opportunity for City's lead therapy? City Therapeutics' lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. That creates a potential opportunity in an established treatment category, but does not demonstrate an advantage over existing medicines. The supplied facts do not identify the candidate's target, clinical stage, dosing schedule or results. Which companies have partnerships with City Therapeutics? City Therapeutics has partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. These relationships broaden the applications being pursued with its technology. They do not establish clinical success, and the supplied facts contain no payments, milestones or royalty terms from which to estimate future revenue. What should investors watch following the IPO? Investors should watch for program priorities, spending plans and evidence connecting RNAi activity to patient benefit. For the lead therapy, efficacy and safety relevant to anticoagulant use will matter. For the broader platform, the central question is whether delivery beyond the liver produces reproducible, therapeutically useful results.

STAAR Surgical appoints Andrew Pilon, OD, as vice president of business development. Monday, October 12, 2026 12:24 AM | Andrew Pilon, OD. | / | LAKE FOREST, Calif. - STAAR Surgical Co. (NASDAQ: STAA), a leader in phakic intraocular lenses (IOLs) with its EVO family of Implantable Collamer Lenses (EVO ICL), has appointed Andrew Pilon, OD, as vice president of business development, which is a new position, the company told VMAIL. Dr. Pilon will report to Warren Foust, STAAR's president and CEO, and work closely with the company's senior leadership team to capitalize on opportunities that support STAAR's innovation strategy and expand its product portfolio, according to the announcement from the company. Dr. Pilon joins STAAR from Johnson & Johnson Vision, where he spent nearly six years as senior director of business development for the surgical vision division. In that role, he led efforts to evaluate and advance strategic partnerships, acquisitions and licensing opportunities across Johnson & Johnson's global ophthalmology portfolio, the announcement noted. "Andrew brings a unique combination of clinical expertise, extensive ophthalmology experience, and a strong track record in strategic growth," said Foust. "Throughout his career, Andrew has demonstrated a talent for maximizing the value of existing technology while strengthening businesses through strategic licensing, partnerships, and structured investments. As we continue to grow EVO ICL, expand into new markets, and evolve our multi-product platform, I am confident that Andrew will help us identify and unlock new opportunities that accelerate innovation and broaden the range of products we can offer to patients and physicians." Under Dr. Pilon's leadership, Johnson & Johnson Vision expanded its global portfolio of strategic investments and partnerships across the optometric and ophthalmic sectors, helping advance long-term growth opportunities spanning its consumables, capital equipment and digital health capabilities, the announcement said. He previously served as Johnson & Johnson's senior director of new ventures and transactions for vision science, focusing on identifying growth opportunities aligned with the strategic priorities of the company's operating companies. Prior to joining Johnson & Johnson, Dr. Pilon held multiple leadership positions at Bausch + Lomb, including roles in professional strategy, corporate development and marketing. "I am thrilled to join the STAAR team during such an exciting time and look forward to helping the company build on its leadership position in lens-based refractive surgery," said Dr. Pilon. "Together, we will further strengthen STAAR's strategic partnerships and alliances, identify promising new technologies, and pursue initiatives that broaden the company's capabilities, including with respect to additional uses of its proprietary Collamer material technology. The opportunities ahead are significant, and we are well-positioned to expand our portfolio and pursue new avenues for innovation and growth." Dr. Pilon trained and practiced as an optometrist and served as a clinical faculty member at the Southern California College of Optometry and the Illinois College of Optometry. He has also participated as an investigator in more than three dozen FDA-regulated clinical trials that contributed to the approval and commercialization of numerous drugs and medical devices. Dr. Pilon has advised the boards of several venture-backed ophthalmic companies on a range of growth initiatives, including leadership development, executive recruitment, capital formation, operational improvement and strategic planning. He holds a doctor of optometry from the Illinois College of Optometry, where he graduated summa cum laude as class valedictorian. He also earned a master of business administration from the University of Nevada, Reno, and a bachelor's degree in molecular biology and biotechnology from McMaster University, the announcement said.